Virus-Like Particle & Nano-Particle Vaccines

4-6 June 2014, Salk Institute for Biological Studies, La Jolla, California, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day Three

Final Conference Programme | Friday 6th June

SESSION 9:
DELIVERY PLATFORMS

Moderator: Charles Richardson (Takeda Vaccines Inc., Bozeman, Montana, USA)

09.00-09.25
‘The synthetic virus-like particle platform: A new approach to antigen delivery’
Arin Ghasparian (Virometix AG, Zurich, Switzerland)

09.25-09.45
‘Fast and efficient assembly platform for enveloped virus-like particles and their use as novel vaccines’
Christian Mittelholzer, Simon Bredl, Corinne John and Sabine Wellnitz (Redbiotec AG, Schlieren, Switzerland)

09.45-10.05
‘Nanoemulsions with advanced surface functionality as therapeutic and prophylactic delivery vehicles’
Frank Sainsbury, Bijun Zeng, Ranjeny Thomas and Anto P.J. Middelberg (The University of Queensland, Lucia, Queensland, Australia)

10.05-10.25
‘Development of a versatile virus-like particle based vaccine delivery platform’
Susan Thrane, Ali E. Salanti, Morten A Nielsen, Mette O. Agerbaek, Thor G. Theander and Adam F. Sander (University of Copenhagen, Copenhagen, Denmark)

10.25-10.45
‘Potentiation of neutralizing antibody responses following DNA vaccination with electroporation’
Kate E. Broderick, Karuppiah Muthumani, Laurent Humeau, David B. Weiner and Niranjan Y. Sardesai (Inovio Inc., Blue Bell, Pennsylvania, USA)

10.45-11.15
Coffee Break & Posters

SESSION 10:
TECHNOLOGY

Moderator: Peter Pushko (Medigen Inc., Frederick, Maryland, USA)

11.15-11.35
‘Rapid total particle quantification: Accelerating the pace of research, development and production’
Mark Rehse and Michael Artinger (ViroCyt, LLC, Boulder, Colorado, USA)

11.35-11.55
‘The WHc-VLP: An ideal platform raise high-titer antibody to targeted epitopes, both linear and structured’
David Whitacre, Amy Tucker, Cory Peters, Joyce Jones, Darrell Peterson and David Milich (VLP Biotech Inc., San Diego, California, USA)

11.55-12.15
‘Flu titer on Chip: A rapid, cost-saving alternative to SRID’
Kathy Rowlen (InDevR Inc., Boulder, Colorado, USA)

12.15-12.35
‘Development of alternative purification steps for virus-like particles using high-throughput experimentation’
Christopher Ladd Effio, Lukas Wenger, Ozan Oetes, Stefan A. Oelmeier and Jurgen Hubbuch (Karlsruhe Institute of Technology, Karlsruhe, Germany)

12.35-13.00
‘Qualitative and quantitative characterization of VLP and nanoparticle samples using electron microscopy and automated image analyses’
Musa Sani (Vironova AB, Stockholm, Sweden)

13.00-14.00
Lunch Break & Posters

SESSION 11:
VACCINES II

Moderator: Greg Glenn (Novavax Inc., Rockville, Maryland, USA)

14.00-14.25
‘Progress in the development of a norovirus VLP vaccine’
Charles Richardson (Takeda Vaccines Inc., Bozeman, Montana, USA)

14.25-14.50
‘Generation of a cholesterol-lowering vaccine that targets PCSK9’
Bryce Chackerian, Erin Crossey, Marcelo Amar, David S. Peabody, John T. Schiller and Alan T. Remaley (University of New Mexico, Albuquerque, New Mexico, USA)

14.50-15.10
‘Development of recombinant baculovirus for high yield production of enterovirus 71 virus-like particle vaccine’
Shih-Yeh Lin, Yao-Chi Chung and Yu-Chen Hu (National Tsing Hua University, Hsinchu City, Taiwan, R.O.C.)

15.10-15.30
‘A viral-like particle vaccine expressing Chikungunya Virus envelope protein induces protective immunity in mice against viral challenge’
Kar Muthumani, Colleen Tingey, Boa HuiHui, Emma L. Reuscal, Peter Block, Sagar Kudchodkar, Nagarajan Muruganandam, Paluru Vijayachar, Kenneth E. Ugen,  J, Joseph Kim, Niranjan Y. Sardesai and David B. Weiner (University of Pennsylvania School of Medicine, Philadelphia, USA)

15.30-15.50
‘Advanced characterization of VLP particles on particle by particle basis using Tunable Resistive Pulse Sensing (TRPS) technology’
Subhash Kalluri (IZON Inc., Cambridge, Massachusetts, USA)

15.50
Closing Remarks & Departure

* This provisional programme is correct at the time of printing. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the final conference programme. A final programme with timings will be available in May 2014.

 

VLPNPV 2014 Delegates

Login details will be supplied after you have registered for the event.

VLPNPV 2014 Venue


VLPNPV 2014 Sponsors

  • Fraunhofer USA
  • Izon
  • Univac
  • SALK Institute
  • Matrivax
  • Medicago
  • NatureGeneTherapy.com
  • Aldevron
  • Malvern
  • John Innes Centre
  • Vironova
  • Novavax
  • Medigen
  • Sanofi Pasteur
  • VLP Biotech
  • Vaccine Research Center
  • Vedantra Pharmaceuticals
  • Virometix Vaccines
  • Mucosis
  • Takeda

VLPNPV 2014 Downloads

VLPNPV 2014 Leaflet

VLPNPV 2014 Mailing List

Name
E-mail Address
What is 2+6-2?